United States: Recent Congressional Actions Bring Drug Pricing Debate Back Into National Spotlight

Ethan Jorgensen-Earp is a Public Affairs Advisor for Holland & Knight's Washington, D.C. office

In late October, Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) introduced the Medicare Drug Price Negotiation Act of 2017 (S. 2011; H.R. 4138), which would allow the Department of Health and Human Services (HHS) to directly negotiate for lower prescription drug prices in Medicare, as Medicaid and the Department of Veterans Affairs are currently permitted to do. The legislation would also strengthen the patient appeals process and restore rebates for low-income beneficiaries under the Medicare Part D program for patients, and would use formularies to establish a fallback price, based on what other federal agencies and foreign governments pay, to take effect if negotiations are unsuccessful. This legislation is significantly more comprehensive than many previously introduced bills that only permit HHS to negotiate drug prices for Medicare Part D without other provisions, and the Sanders/Cummings legislation has garnered significant press attention and even White House meetings on the subject.

While it may seem that Democrats face an uphill battle to pass these bills, they may find an unlikely ally in their quest to lower prescription drug costs: President Donald Trump. On the campaign trail, the President heavily criticized the pharmaceutical industry for soaring prescription drug costs. After taking office, the President continued to lambaste "outrageous" drug prices and promised to develop a "fair and competitive bidding process" to bring down prices for consumers. The introduction of these bills highlights a key issue on which Democrats believe they may be able to find common ground with President Trump, an issue that has gained renewed attention with Congress' consideration of Alex Azar to replace former HHS Secretary Tom Price.

A Popular Issue

Prescription drug prices have increasingly become a highly salient political issue. Highly publicized cases of exorbitant drug price increases, such as with certain insulin products and HIV medications, have shifted the issue into popular discourse. Recent polls indicate that nearly eight in ten Americans believe prescription drug costs are unreasonable, with six in ten stating that lowering drug costs should be a priority for President Trump and Congress.1 And for good reason, too: the growth in spending on prescription drugs has continually outpaced that of all other parts of the health care sector, and by 2020, net spending on pharmaceuticals will reach $400 billion, up from $310 billion in 2015.2 Studies have found that escalating drug costs have left consumers with higher insurance premiums, increased out-of-pocket costs, and reduced access to treatment. Taxpayers must also foot the bill for increased drug costs in the form of spending increases to public programs such as Medicare and Medicaid.3

In August 2016, researchers at Harvard Medical School undertook a comprehensive examination of the reasons for the rapid rise in drug prices. Their findings, published in the Journal of the American Medical Association, highlighted several key factors behind rising drug costs.4 For example, unlike in countries with national health programs that can negotiate drug prices or decide not to cover highly expensive drugs, drug manufacturers in the U.S. generally set their own prices.  Additionally, they found, abuse of the patent system and other regulatory boundaries may hinder generic drugs from being brought to the market that would offer consistent price competition.  Research from the Pew Charitable Trusts also indicates that a growing share of expensive "specialty drugs," which are used to treat complex, chronic conditions like cancer and HIV, are entering the market.5

Policymakers have taken note of this growing concern. Food and Drug Administration (FDA) Commissioner Scott Gottlieb has committed to expediting the approval of cheaper generic drugs and combatting anti-competitive behaviors that some pharmaceutical companies have utilized to prevent generics from entering the market. On social media and during rallies, President Trump has criticized "ripoff" drug prices, likening the profit margins of pharmaceutical companies to "getting away with murder." In June and October of this year respectively, the Senate Health, Education, Labor, and Pensions (HELP) Committee held hearings to discuss the causes of and solutions to rising prescription drug costs, and members of Congress have introduced over 25 bills to tackle the issue with varying solutions. 

Proposed Solutions

Lawmakers have introduced an abundance of bills to address the rising costs of prescription drugs. In addition to permitting Medicare negotiation, one set of proposals revolves around the importation of drugs from Canada. The Affordable and Safe Prescription Drug Importation Act (S. 469; H.R. 1245), introduced in February, would direct HHS to publish regulations that would allow entities, including wholesalers and pharmacies, to import "qualifying prescription drugs" from certified Canadian sellers. The legislation also allows HHS to open up importation of drugs from other foreign countries after two years with proper certification. More focused bills, such as the Safe and Affordable Drugs from Canada Act (S. 92; H.R. 1480) allows limited, per-patient importation from Canada. While importation bills such as these are gaining bipartisan steam, some in Congress have alleged that such a system could infiltrate the U.S. medicine supply with counterfeit or adulterated products.

Another set of proposals seek to increase the competitiveness of the pharmaceutical marketplace. For instance, the bipartisan Lower Drug Costs Through Competition Act (H.R. 749) would incentivize companies to develop generic drugs by creating a new generics Priority Review Voucher, which would be awarded to manufacturers that bring a drug to market where there is a monopoly or drug shortage. Similar voucher programs have drawn mixed reviews in attempts to spur drug development for tropical and pediatric rare diseases. Other legislation, such as the bipartisan Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974), would target two tactics used by manufacturers to delay entry of generic drugs to the market; specifically, sample sharing and shared safety protocols. These bills pinpoint particular issues within the prescription drug market, but critics argue that that the federal government should play a more active role in regulating drug costs.

Such critics have introduced their own set of legislative solutions. These include the Stop Price Gouging Act (S. 1369; H.R. 2974), which would require drug companies to report and justify drug price increases to the Inspector General of HHS, with the promise of financial penalties for noncompliance, and the Prescription Drug and Medical Device Price Review Board Act (H.R. 6501), introduced last Congress, which would establish a national review board that would review drug prices could take enforcement action against manufacturers that charge consumers excessively.

Other attempts are less targeted. Sen. Al Franken (D-MN) and Rep. Janice Schakowsky (D-IL) have introduced a seemingly "catch-all" solution to lower prescription drug costs. The bipartisan, but almost solely Democratic-led, Improving Access to Affordable Prescription Drugs Act (S. 771; H.R. 1776) seeks to comprehensively address what many of the aforementioned bills attempt to do singularly. The bill includes a broad range of proposals, including allowing Medicare to negotiate lower drug prices in Part D, restoring rebates on drugs covered under Part D for low-income beneficiaries, permitting the importation of prescription drugs, capping out-of-pocket costs for drugs in private insurance plans, and reducing monopolies for brand-name drugs. While many of these proposals lack broad political support, they may serve as markers to generate conversation around the drug pricing issue that may distill down into bipartisan proposals in the future, provided both Congress and the Administration see eye to eye.


Although public support for a solution to high prescription drug prices remains strong, several obstacles stand in the way of a legislative fix. The bills described above span the ideological spectrum, and coming to a compromise on the substantive details of a legislative solution may be difficult to achieve. Advocates of a stronger federal role in lowering drug costs may reject competition-based bills as weak, short-term solutions, while advocates of limited government and market-based approaches may stress the federal overreach of the more expansive proposals. Indeed, many of these ideas have been introduced in bills during previous Congresses without success.

Additionally, with tax reform, immigration, the budget, and other "must-pass" bills such as a reauthorization of the Children's Health Insurance Program (CHIP) on the minds of congressional leadership, it is unlikely that either chamber will take the initiative to dive into a prescription drug cost bill anytime soon. And although the President has issued strong statements against the drug industry, his administration has invested little political capital in the issue. Indeed, a leaked draft of an executive order designed to bring down drug prices earlier this year was roundly considered industry-friendly and unlikely to substantially decrease drug costs.6 Furthermore,  President Trump's nominee for HHS Secretary, Alex Azar, has been criticized in Democratic circles because of his close ties to the pharmaceutical industry. If movement on the issue occurs, it will likely begin with proposed modifications to existing programs, such as recent proposals to amend the 340B Drug Pricing Program, and while market-based approaches may certainly be viable in this political environment if Republicans retain a majority in Congress, negotiation and implementation of such approaches can be unpredictable, solutions may be potentially costly depending on cost-shifting and other factors, and there will likely be push-back from numerous influential parties. Thus, while prescription drug prices and public pressure to solve the issue remain high, a quick solution is likely not on the horizon any time soon given competing congressional interests and implementation issues.


1 Kirzinger A. et al., " Kaiser Health Tracking Poll - Late April 2017: The Future of the ACA and Health Care & the Budget," April 26, 2017.

2 Pew Charitable Trusts, " Drug Spending Research Initiative."

3 Id.

4 Kesselheim A., Avorn J., Sarpatwari A., " The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform," Journal of the American Medical Association, August 2016; 316(8):858-871. 

5 Pew Charitable Trusts, " Drug Spending Research Initiative."

6 Kaplan, S., Thomas, K. " Draft Order on Drug Prices Proposes Easing Regulations," June 20, 2017.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
Akin Gump Strauss Hauer & Feld LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
Akin Gump Strauss Hauer & Feld LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions